GlassScriptPhysician profile
Udit Narain Verma
NPI 1033178165
$8,002.40
in general payments reported to CMS, 2019-2025
9 companies · $19.68 in 2025
The $19.68 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,480 · 2021: $366 · 2022: $117 · 2024: $2,020 · 2025: $19.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,620 · Consulting Fee: $400 · Food and Beverage: $19.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,620.00 |
| Consulting Fee | $400.00 |
| Food and Beverage | $19.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,479.75 | 2019 | |
| Exelixis INC. | $1,620.00 | 2024 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $400.00 | 2024 | Imfinzi |
| Genzyme Corporation | $350.00 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $95.91 | 2022 | |
| Alexion Pharmaceuticals, INC. | $37.06 | 2021-2022 | |
| Glaxosmithkline, LLC. | $19.68 | 2025 | Ojjaara |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Udit Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.